Zafgen Inc. (NASDAQ:ZFGN) fell 1% on Tuesday . The company traded as low as $6.72 and last traded at $6.85, with a volume of 184,623 shares changing hands. The stock had previously closed at $6.92.

A number of brokerages have weighed in on ZFGN. FBR & Co reissued a “buy” rating on shares of Zafgen in a report on Monday, June 13th. Zacks Investment Research raised shares of Zafgen from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a report on Thursday, May 12th. Leerink Swann reaffirmed a “hold” rating and set a $6.00 price objective on shares of Zafgen in a research note on Monday, April 11th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $19.00 price objective on shares of Zafgen in a research note on Tuesday, April 5th. Four investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $11.94.

The firm’s 50-day moving average price is $6.45 and its 200 day moving average price is $6.58. The firm’s market cap is $177.81 million.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.09. During the same period last year, the business earned ($0.53) earnings per share. Analysts forecast that Zafgen Inc. will post ($2.81) earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Zafgen stock. Oxford Asset Management acquired a new position in Zafgen Inc. (NASDAQ:ZFGN) during the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 236,362 shares of the biopharmaceutical company’s stock, valued at approximately $1,497,000. Oxford Asset Management owned 0.87% of Zafgen at the end of the most recent quarter.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.